Skip to main content

Table 5 ELISpot IFN-γ activity of CSP peptide pools and predicted 8-10mer epitopes within these pools (strategy 1 and strategy 2)

From: Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)

Pool

Vol.

Epitope no.

Epitope sequence

AA no.

HLA allele group

HLA supertype

IC50nM

Pool sfc/m

Epitope sfc/m

Percent of pool

Cp1

581

E1

FLFVEALFQE

13-22

A*02:01

A02

258

ND

49

 

Cp1

1563

E1

FLFVEALFQ E

13-21

A*29:02

A01A24

422

126

105

83.3

  

E1

FLFVEALF QE

13-20

A*29:02

A01A24

109

   

Cp1

692

E2

FVEALFQEY

15-23

B*35:01

B07

68

399

268

67.2

Cp1

1273

E2

FVEALFQEY

15-23

A*01:01

A01

63

69

89

129

Cp1

692

E3

LFVEALFQEY

14-23

A*30:02

A01

63

ND

259

 

Cp1

692

E3 (E2)

LFVEALFQEY

15-23

B*35:01

B07

68

399

259

64.9

Cp1

1273

E3 (E2)

LFVEALFQEY

15-23

A*01:01

A01

63

69

99

144

Cp9

371

E14

SVFNVVNSSI

376-385

A*68:02

A02

18

79

28

35.4

Cp9

581

E14

SVFNVVNSSI

376-385

A*02:01

A02

470

13

80

615

Cp9

401

E14

SVFNVVNSSI

377-385

A*23:01

A24

1801

434

104, 72

242, 167

Cp9

1563

E18

LIMVLSFLF

387-395

A*29:02

A01A24

190

64

156

244

Cp9

371,2

E18

LIMVLSFLF

387-395

B*15:03

B27

111

794

55, 38

69.6, 48.1

Cp9

401

E18

LIMVLSFLF

387-395

A*23:01

A24

282

434

290, 166

674, 386

Cp1

631

E19

AILSVSSFLF

6-15

A*24:03

A24

1088

ND

41

 

Cp1

1253

E20

SVSSFLFVEA

9-18

A*02:01

A02

25

27

33

122

Cp1

681

E21

SFLFVEALF

12-20

A*24:02

A24

104

ND

34

 

Cp1

371,2

E21

SFLFVEALF

12-20

A*23:01

A24

104

364

53, 53

147, 147

Cp1

401

E21

SFLFVEALF

12-20

A*23:01

A24

104

1634

313, 197

192, 121

Cp1

1563

E21

SFLFVEALF

12-20

A*29:02

A01A24

245

120

240

200

Cp9

1253

E22

IMVLSFLFL

388-396

A*02:01

A02

59

58

29

50.0

  1. This table includes all 19 epitope-specific responses that were positive among the 35 that were tested. The presence of two results in the epitope response column (second from right) indicates that two separate experiments were performed. E18 is a 9mer sequence predicted by NetMHC within E17 (Table 4) and was synthesized rather than E17 and tested with three volunteers immunized with Ad-CA or Ad-C. Three of the 9mer sequences that are underlined indicate additional class I-restricted sequences predicted by NetMHC contained within E1 and E14 epitopes respectively. E1 was positive with both the volunteer predicted to recognize the full sequence and the volunteer predicted to recognize two nested epitopes. E14 was positive for both the two volunteers predicted to recognize the full sequence and the one volunteer predicted to recognize the nested epitope. A single assay was performed for v69 and E3; however, E3 contains the E2 sequence that is underlined and has a different predicted restriction than E3, so both are listed. E14 contains a predicted A*23:01-restricted epitope that is underlined.
  2. 1PBMC from 28 days after first Ad-C immunization; 2PBMC from 19 days after second Ad-C immunization; 3PBMC from 28 days after Ad-CA immunization; 4The response to the peptide pool was not done in the second assay.
  3. ND, Not Done.